CB07-Exatecan

CAT: 0804-HY-160015-01Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-160015-01Size:1 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
CB07-Exatecan is an ADC drug-Linker conjugate that can be used for the synthesis of ADCs. ADC conjugated with CB07-Exatecan and trastuzumab inhibits the growth of HER2-positive cancer cells. CB07-Exatecan can be used in cancer research[1].
CAS Number
[2879247-31-9]
UNSPSC
12352203
Target
Drug-Linker Conjugates for ADC; Topoisomerase
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cb07-exatecan.html
Purity
98.97
Solubility
DMSO : 100 mg/mL (ultrasonic; warming)
Smiles
O=C(C=CC1=O)N1CC(N[C@@H](CCNC(CCOCCOCCOCCOCCOCCOCCOCCOC)=O)C(N[C@@H](C(C)C)C(N[C@@H](CCCNC(N)=O)C(NC(C=C2)=CC=C2COC(N[C@@H]3C4=C5C(C(N6C5)=CC([C@](O)(C(OC7)=O)CC)=C7C6=O)=NC8=CC(F)=C(C)C(CC3)=C84)=O)=O)=O)=O)=O
Molecular Formula
C71H94FN11O22
Molecular Weight
1472.56
References & Citations
[1]Weijia Tang, et al. Method for treating her2-positive solid tumor. Patent WO2023198079A1.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
ADC Related
Clinical Information
No Development Reported
Isoform
Camptothecins

Popular Products